Interleukin 6 and high-sensitivity C-reactive protein are potential predictive markers of response to infliximab in hidradenitis suppurativa

J Am Acad Dermatol. 2017 Jan;76(1):156-158. doi: 10.1016/j.jaad.2016.08.036.

Authors

Henri Montaudié¹, Barbara Seitz-Polski², Aurore Cornille², Sylvia Benzaken², Jean-Philippe Lacour¹, Thierry Passeron³

Affiliations

¹ Department of Dermatology, University Hospital of Nice, Nice, France.
² Immunology Laboratory, University Hospital of Nice, Nice, France.
³ Department of Dermatology, University Hospital of Nice, Nice, France; Institut National de la Santé et de la Recherche Médicale (INSERM), U1065, Centre Méditerranéen de Médecine Moléculaire, Team 12, Nice, France. Electronic address: [email protected].

PMID: 27986139
DOI: 10.1016/j.jaad.2016.08.036

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Biomarkers / blood
C-Reactive Protein / metabolism*
Dermatologic Agents / therapeutic use*
Female
Hidradenitis Suppurativa / blood*
Hidradenitis Suppurativa / drug therapy*
Humans
Infliximab / therapeutic use*
Interleukin-1beta / blood
Interleukin-6 / blood*
Male
Middle Aged
Pilot Projects
Predictive Value of Tests
Prospective Studies
Quality of Life
Severity of Illness Index
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Tumor Necrosis Factor-alpha / blood
Young Adult

Substances

Biomarkers
Dermatologic Agents
Interleukin-1beta
Interleukin-6
Tumor Necrosis Factor-alpha
C-Reactive Protein
Infliximab